Skip to main content

Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement

Written by Customer Service on . Posted in Public Companies.

FULLERTON, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) — Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”), a biopharmaceutical company developing novel therapies for cancer and other serious diseases, today announced that its common stock was transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective August 4, 2026, and that the Nasdaq Hearings Panel (the “Panel”) has granted the Company additional time to demonstrate compliance with Nasdaq’s minimum bid price requirement.

The transfer to the Nasdaq Capital Market allows the Company’s common stock to continue trading on Nasdaq under its existing ticker symbol, “LIMN.” The Nasdaq Capital Market is one of Nasdaq’s three listing tiers.

In addition, the Panel has granted the Company’s request for an extension to demonstrate compliance with the applicable minimum bid price requirement. Under the Panel’s decision, the Company has until September 3, 2026 to demonstrate compliance with the Bid Price Rule.

The Company intends to take the actions necessary to regain compliance with the minimum bid price requirement within the period granted by the Panel. The Company’s common stock will continue to trade on the Nasdaq Capital Market during this period, subject to the Company’s compliance with the Panel’s decision and other applicable Nasdaq continued listing requirements.

“We are pleased to have completed the transfer to the Nasdaq Capital Market and appreciate the Panel providing the Company additional time to demonstrate compliance with the minimum bid price requirement,” said Scott Dam, Chief Financial Officer of Liminatus Pharma. “Maintaining our Nasdaq listing remains an important priority as we continue executing on our corporate and clinical development strategy.”

About Liminatus Pharma, Inc.

Liminatus Pharma, Inc. is a biopharmaceutical company focused on developing novel therapies for cancer and other serious diseases. The Company’s development portfolio includes IBA101, a humanized anti-CD47 monoclonal antibody being developed as a next-generation immune-modulating cancer therapy, together with additional therapeutic assets acquired through the Company’s strategic transactions.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable federal securities laws. Forward-looking statements include, among other things, statements regarding the Company’s ability to regain compliance with Nasdaq’s continued listing requirements, the timing and effectiveness of actions taken to regain compliance, the Company’s continued listing on the Nasdaq Capital Market, and the Company’s corporate and clinical development plans. These statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. There can be no assurance that the Company will regain compliance with the minimum bid price requirement within the period granted by the Panel or maintain compliance with other applicable Nasdaq listing requirements. The Company undertakes no obligation to update any forward-looking statements except as required by applicable law.

For more information, please contact:

Chris Kim, Chief Executive Officer
chris@liminatus.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.